Nutex Health Inc.
No SEC Form 4 filings for $NUTX in the last 30 days.
Nutex Health Inc. (NASDAQ: NUTX) reported Q2 2026 results for the three and six months ended June 30, 2026. Net income attributable rose to $65.8M (diluted EPS $9.38) for Q2, versus a loss in 2025. Six-month net income was $112.6M (EPS $15.87). Revenue fell to $427.2M for six months. Operating cash flow was $109.7M. Hospital visits increased.
Nutex Health Inc. (NUTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 nutx-20260630xexx99.htm EX-99.1 Document NUTEX HEALTH REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS HOUSTON, TX − (PRNewswire) – AUGUST 6, 2026 – Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), today announced financial results for the three and six
Nutex Health Inc. (NUTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. nutx-20260715 0001479681 FALSE 0001479681 2026-07-15 2026-07-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
Over the past 7 days, alphai's AI scored 2 news stories mentioning NUTX (Nutex Health Inc.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent NUTX coverage spans financial news, earnings and regulation.
The earnings release highlights improving profitability and operating cash flow, but also shows revenue declines and ongoing reliance on IDR/arbitration economics.
The filing shows a sharp profitability rebound and improved cash generation, but also highlights revenue declines tied to IDR-related timing and contract services cost reductions.
The 8-K discloses a contract amendment tied to CMS IDR fee reductions, implying lower dispute-related arbitration costs and potentially improved economics.
Near-term catalyst is the second-week-of-August Q2 2026 financial release, which can confirm or reverse the recent momentum.
The article frames Nutex’s Medicare opt-out as a business model that may increase regulatory and litigation risk while affecting patient-flow and payer mix.
alphai scores every news story that mentions NUTX with an AI model for sentiment and relevance, and aggregates insider trades from Nutex Health Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Nutex Health Inc. (NASDAQ: NUTX) reported Q2 2026 results for the three and six months ended June 30, 2026. Net income attributable rose to $65.8M (diluted EPS $9.38) for Q2, versus a loss in 2025. Six-month net income was $112.6M (EPS $15.87). Revenue fell to $427.2M for six months. Operating cash flow was $109.7M. Hospital visits increased.
6 min readNutex Health Inc. (NUTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 nutx-20260630xexx99.htm EX-99.1 Document NUTEX HEALTH REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS HOUSTON, TX − (PRNewswire) – AUGUST 6, 2026 – Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), today announced financial results for the three and six
7 min readNutex Health Inc. (NUTX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. nutx-20260715 0001479681 FALSE 0001479681 2026-07-15 2026-07-15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):
4 min readThe article profiles five biotech/healthcare stocks and cites recent catalysts and upcoming events. Glaukos (GKOS) highlights Epioxa launch and raised 2026 sales guidance ahead of Q2 2026 results July 29, 2026. TG Therapeutics (TGTX) cites BRIUMVI trial updates and Q2 results early August. Corcept (CORT) points to Lifyorli progress and raised guidance. Relay (RLAY) and Nutex Health (NUTX) note Phase 3 and upcoming quarterly results. It lists large post-publication price gains for each.
7 min readSTAT reports some for-profit ER operators are opting out of Medicare, which can exempt them from EMTALA’s requirement to screen and stabilize all arrivals. Houston-based Nutex Health, which runs 27 hospitals in 12 states, reportedly declines Medicare at most sites. Patients allege payment demands before exams; Nutex denies. STAT says Nutex revenue rose to $875M in 2025.
6 min readThe article cites CMS data showing U.S. health expenditures rose 7.2% to $5.3T in 2024, with hospital care at $1.63T (+8.9%) and physician/clinical services at $1.11T (+8.1%). It then lists 10 “medical care facilities” stocks ranked by analyst price-target upside (min 20%), highlighting HCA (~21.9% upside) and Nutex (target implies ~25.4% upside).
7 min readSTAT reports some for-profit ER operators are opting out of Medicare, which can exempt them from EMTALA’s requirement to screen and stabilize all arrivals. Houston-based Nutex Health, which runs 27 hospitals in 12 states, reportedly declines Medicare at most sites. Patients described being asked to pay before exams. Nutex denies refusing care; STAT says revenue rose to $875M in 2025.
7 min readAn amendment to a Schedule 13G/A filing reveals that Pertento-related entities and Eduardo Marques have reported significant holdings in Nutex Health (NUTX). Pertento Partners LLP, Pertento Advisors LLC, and Eduardo Marques each hold 405,029 shares, representing 5.9% of the common stock, while Pertento Master Fund Limited owns 361,201 shares, or 5.3%. The filing, dated May 1, 2026, and signed May 7, 2026, indicates a passive investment intent.
2 min readNutex Health Inc. (NUTX) reported its first-quarter revenue of $216.5 million, falling short of the FactSet estimate of $227.8 million. This financial update follows another recent report from "MT Newswires" on the same day, indicating that the company posted Q1 EPS of $6.52, surpassing the FactSet estimate of $3.99. The articles are reserved for members to view the full content.
3 min readNutex Health, a small-cap company in the Pharmaceuticals & Biotechnology sector, has seen its valuation grade upgraded from fair to attractive due to strong financial performance. The company exhibits a low P/E ratio of 2, impressive annual net sales growth of 229.14%, and a high return on equity of 83.15%. These metrics highlight effective management, operational efficiency, and a compelling valuation, attracting significant institutional holding.
2 min read
